RecruitingPhase 2NCT06978725

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

Sponsor

Priovant Therapeutics, Inc.

Enrollment

28 participants

Start Date

Apr 9, 2025

Study Type

INTERVENTIONAL

Conditions

Cutaneous Sarcoidosis

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oral Brepocitinib and a drug called Oral Placebo for people with cutaneous sarcoidosis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOral Brepocitinib

Drug: Oral Brepocitinib

DRUGOral Placebo

Drug: Oral Placebo

Locations(4)

Clinical Trial Site

San Francisco, California, United States

Clinical Trial Site

Durham, North Carolina, United States

Clinical Trial Site

Philadelphia, Pennsylvania, United States

Clinical Trial Site

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06978725